1 results match your criteria: "Department of Neuropsychiatry Osaka Medical and Pharmaceutical University Takatsuki Osaka Japan.[Affiliation]"
Article Synopsis
- - The review discusses advancements in Alzheimer’s dementia treatments, noting the shift from traditional therapies that target acetylcholine and NMDA receptors towards more innovative interventions due to an aging population.
- - It highlights the recent FDA approvals of aducanumab and lecanemab, and presents seven key drugs currently in Phase III trials, explaining their mechanisms and trial details in the U.S. and Japan.
- - The focus is on therapies aimed at amyloid reduction, tau protein management, drug repositioning, and new small molecules, while acknowledging unsuccessful candidates like Gantenerumab and Solanezumab; the future of these treatments remains uncertain but holds potential promise for patients.